profit from every $100 of sales.
$0$100
Passage Bio
$4.25+5.99% today
-50.2% in 1 year
1-year low $3.321-year high $19.85
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Passage Bio sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$45.5 million of profit last year.
SalesProfit
Passage Bio vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Passage Bio | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Passage Bio's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -135 | -103 | -65 | -43 | |
| -132 | -99 | -62 | -42 | |
| -136 | -102 | -65 | -46 | |
| -50.00 | -37.20 | -21.40 | -14.35 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 244 | 151 | 102 | 62 |
| Cash | 35 | 22 | 38 | 46 |
| Total debt | 27 | 26 | 25 | 24 |
| Total liabilities | 42 | 39 | 41 | 44 |
| 201 | 111 | 61 | 19 | |
| 3 | 3 | 3 | 3 | |
| -46.8% | -59.1% | -59.4% | -79.7% | |
| -67.6% | -91.7% | -105.7% | -242.7% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -118 | -78 | -48 | -32 | |
| 5 | 0 | 0 | – | |
| -123 | -78 | -48 | -32 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 19 | 11 | 6 | 3 |
Valuation
- –
- –
- –
- 1.4×
- –
- –
- 0.3×
- -230.4%
- -332.9%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -238.3%
- -74.6%
- -150.9%
- -103.3%
- -255.0%
- –
Growth
- –
- –
- +34.3%
- –
- +4.4%
Financial health
- 0.8×
- 0.49
- 15.8%
- –
- 1.73
- 1.73
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 20%of 884
What analysts expect
- Average price target
- $10.00
- Range
- $7.00 – $15.00
- 3 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 12, 2026 | -2.36 | -2.15 | −9.8% |
| Mar 3, 2026 | -4.08 | -2.19 | −86.3% |
| Nov 10, 2025 | -2.44 | -2.64 | +7.6% |
| Aug 12, 2025 | -2.96 | -4.00 | +26.0% |
| May 13, 2025 | -5.00 | -4.80 | −4.2% |
| Mar 4, 2025 | -0.20 | -0.21 | +4.8% |
| Nov 13, 2024 | -0.31 | -0.23 | −34.8% |
| Aug 8, 2024 | -0.26 | -0.31 | +16.1% |
News
Optimism Is Building for Passage of Crypto's Clarity Act. These 3 Crypto Stocks Need to Be On Your Investment Radar.Yahoo Finance · Aug 26, 2026U.S. military says it aided passage of 660 million barrels of oil through Strait of Hormuz since MayCNBC · Aug 21, 2026Trump calls for passage of a key cryptocurrency bill as it falters in the Senate: ‘We need Congress to take the next step’MarketWatch · Aug 19, 2026The newest story we have is from Aug 26, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
47No pass
Benjamin Graham
51No pass
Philip Fisher
31No pass
Peter Lynch
52No pass
Joel Greenblatt
100Pass
Charlie Munger
20No pass
Terry Smith
19No pass
Questions about Passage Bio
Is Passage Bio a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Passage Bio AI analysis
What does Passage Bio do?
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It is in Biotechnology.
Does Passage Bio pay a dividend?
No. Passage Bio does not pay a dividend at the moment.
Is Passage Bio stock halal?
No. Passage Bio does not pass our halal screen: its debt is 176% of its market value, at or above the 33% limit. How we check
How has Passage Bio stock done over the past year?
Down 50.2% over the past twelve months, to $4.25. It traded between $3.32 and $19.85 and is 78.6% below its high.
Who are Passage Bio's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Passage Bio's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.